Posted by Michael Wonder on 31 Jul 2018
Special or standard pricing arrangements apply?
1 August 2018 - More new medicines have been listed on the PBS today with a special pricing arrangement.
The August 2018 issue of the Schedule of Pharmaceutical Benefits includes a number of new/revised listings. Those listed with a special pricing arrangement (SPA) have been bolded (see below).
- Aclidinium bromide with eformoterol fumarate dihydrate (Brimica Genuair) - restriction change
- Follitropin delta (Rekovelle) - new medicine
- Glecaprevir with pibrentasvir (Maviret) - new combination product
- Ibrutinib (Imbruvica) - new indication
- Indacaterol maleate with glycopyrronium bromide (Ultibro Breezhaler) - restriction change
- Insulin degludec with insulin aspart (Ryzodeg) - new combination product
- Nivolumab (Opdivo) - new indication
- Peginterferon alfa-2a (Pegasys) - new indication
- Perampanel hemisesquihydrate (Fycompa) - new indication
- Pirfenidone (Esbriet) - new strength
- Tiotropium bromide monohydrate with olodaterol hydrochloride (Spiolto Respimat) - restriction change
- Vilanterol trifenatate with umeclidinium bromide (Anoro Ellipta) - restriction change
Nowadays, most new medicines are listed on the PBS with a SPA. One could mount an argument that this has become standard pricing practice for new medicines.
MAESTrO Database has compiled a list of all medicines that have been listed on the PBS with a SPA. Contact MAESTrO Database for more details.
Read Summary of Changes
Posted by:
Michael Wonder